AKT1 and metabolic dysfunction-associated steatotic liver disease: has been associated with non-alcoholic fatty liver disease (NAFLD), promoting hepatic triglyceride accumulation by inhibiting AKT phosphorylation, a key event in insulin signaling [56,64].